In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a ...
An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...
New York, NY (April 22, 2024) – In a scientific breakthrough, Mount Sinai researchers have revealed the biological mechanisms by which a family of proteins known as histone deacetylases (HDACs) ...
TEL AVIV, Israel, March 18, 2026 /PRNewswire/ -- Evinature, a pioneer in evidence-based nutraceutical formulations designed to support digestive health and help individuals manage chronic bowel ...
The U.S. Food and Drug Administration (FDA) approved mirikizumab, on October 26, 2023, a highly effective new treatment for ulcerative colitis (UC), offering a new option to patients battling this ...
A new LOCAL online community built for you. Click now to see all the available groups. More than a quarter of people who got the treatment, called tulisokibart, went into remission FRIDAY, Sept. 27, ...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results